Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Gastrointestinal 1

Conditions

Neoplasms 2Neoplasm Metastasis 2Pancreatic Neoplasms 1Melanoma 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Gallbladder Neoplasms 1Colorectal Neoplasms 1Cholangiocarcinoma 1Breast Neoplasms 1Biliary Tract Neoplasms 1

Interventions

Gemcitabine 12Cisplatin 10pembrolizumab 7Fluorouracil 7Leucovorin 6Oxaliplatin 5durvalumab 3Capecitabine 3zanidatamab 2Paclitaxel 2Irinotecan 2Folfox protocol 2Bevacizumab 2vandetanib 1tucatinib 1trastuzumab deruxtecan 1seribantumab 1merestinib 1lenvatinib 1irinotecan sucrosofate 1galactomannan 1fludarabine 1exatecan 1bintrafusp alfa protein, human 1becatecarin 1aldesleukin 1Trastuzumab 1Temozolomide 1Tegafur 1S 1 (combination) 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Gallbladder Neoplasms × merestinib × Clear all
NCT03027284 2020-05-19

A Study of Merestinib (LY2801653) in Japanese Participants With Advanced or Metastatic Cancer

Eli Lilly and Company

Phase 1 Completed
19 enrolled
GastrointestinalLymphoid

Gallbladder Neoplasms, Lymphoma, Non-Hodgkin, Neoplasm Metastasis, Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡